Mark Grabarczyk, MD
Cardiovascular Disease · Greenville, SCNPI 1134168941
Payments from drug & device makers
Across 404 payments — averaging $193.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$54K
- E.r. Squibb & Sons, L.L.C.$16K
- Medtronic$1K
- Edwards Lifesciences$1K
- Abiomed$886
- Johnson & Johnson$662
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,646100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 30 | $53,791 |
| E.r. Squibb & Sons, L.L.C. | 8 | $16,380 |
| Medtronic(2 entities) | 54 | $1,484 |
| Edwards Lifesciences | 35 | $1,420 |
| Abiomed | 28 | $886 |
| Johnson & Johnson | 53 | $662 |
| Boston Scientific | 28 | $542 |
| Atricure, Inc. | 17 | $496 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $343 |
| AstraZeneca | 20 | $289 |
| Novartis | 15 | $242 |
| Cardiovascular Systems Inc. | 11 | $188 |
| Merck | 9 | $162 |
| Teleflex LLC | 3 | $155 |
| Pfizer | 11 | $152 |
| Shockwave Medical, Inc | 9 | $135 |
| Sanofi-aventis U.S. LLC | 6 | $122 |
| Abbott | 6 | $119 |
| Cvrx, Inc. | 4 | $96 |
| Boehringer Ingelheim | 6 | $94 |
| Philips North America LLC | 4 | $82 |
| Gilead | 5 | $65 |
| Surmodics, Inc. | 2 | $49 |
| Penumbra, Inc. | 1 | $48 |
| Novo Nordisk | 2 | $47 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $34 |
| Terumo Medical Corporation | 2 | $31 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $30 |
| Acist Medical Systems, Inc. | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Livanova USA, Inc. | 1 | $23 |
| Angiodynamics, Inc. | 1 | $20 |
| CMP Pharma, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$78,303 in reported general payments places this provider in the 90th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 370 | $384,296 |
| XareltoRivaroxaban | 110 | $105,999 |
| Repatha SureclickEvolocumab | 114 | $103,741 |
| EntrestoSacubitril/Valsartan | 20 | $29,920 |
| BrilintaTicagrelor | 47 | $25,835 |
| MultaqDronedarone Hcl | 12 | $25,011 |
| Praluent PenAlirocumab | 30 | $20,216 |
| Metoprolol Succinate | 473 | $6,407 |
| Ranolazine ErRanolazine | 59 | $5,747 |
| Rosuvastatin Calcium | 285 | $5,238 |
| ClopidogrelClopidogrel Bisulfate | 392 | $4,159 |
| Atorvastatin Calcium | 404 | $4,157 |
| Carvedilol | 282 | $2,880 |
| Losartan Potassium | 209 | $2,632 |
| Ezetimibe | 63 | $2,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $152 | $384,296370 claims |
| Johnson & JohnsonXarelto | $662 | $105,999110 claims |
| NovartisEntresto | $242 | $29,92020 claims |
| AstraZenecaBrilinta | $289 | $25,83547 claims |
| Sanofi-aventis U.S. LLCMultaq | $122 | $25,01112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Greenville
- James MerriamGreenville$728K
- Arthur EberlyGreenville$438K
- Gregory SanGreenville$429K
- Dev VazGreenville$257K
- John CebeGreenville$152K
- David McNeelyGreenville$78K
- Christopher SalmonGreenville$54K
- Christopher SmithGreenville$47K
- Arthur SiachosGreenville$29K
- Jon BittrickGreenville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.